Noile-Immune Biotech Inc announced that it has received ¥999.998803 million in funding from BINEX Co., Ltd.
March 11, 2021
Share
Noile-Immune Biotech Inc. announced a private placement of 256,871 common shares at a price of ¥3,893 per share for the gross proceeds of ¥999,998,803 with existing investor BINEX Co., Ltd. (KOSDAQ:A053030) on March 12, 2021. The investor now holds 455,565 shares and 5.8% stake in the company. The transaction was approved by the board of directors of investor.
On the same date, the company has received its first tranche.
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.